Literature DB >> 10358073

Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility.

J K Voice1, R L Klemke, A Le, J H Jackson.   

Abstract

Human cells contain four homologous Ras proteins, but it is unknown whether each of these Ras proteins participates in distinct signal transduction cascades or has different biological functions. To directly address these issues, we assessed the relative ability of constitutively active (G12V) versions of each of the four Ras homologs to activate the effector protein Raf-1 in vivo. In addition, we compared their relative abilities to induce transformed foci, enable anchorage-independent growth, and stimulate cell migration. We found a distinct hierarchy between the four Ras homologs in each of the parameters studied. The hierarchies were as follows: for Raf-1 activation, Ki-Ras 4B > Ki-Ras 4A >>> N-Ras > Ha-Ras; for focus formation, Ha-Ras >/= Ki-Ras 4A >>> N-Ras = Ki-Ras 4B; for anchorage-independent growth, Ki-Ras 4A >/= N-Ras >>> Ki-Ras 4B = Ha-Ras = no growth; and for cell migration, Ki-Ras 4B >>> Ha-Ras > N-Ras = Ki-Ras 4A = no migration. Our results indicate that the four Ras homologs significantly differ in their abilities to activate Raf-1 and induce distinctly different biological responses. These studies, in conjunction with our previous report that demonstrated that the Ras homologs can be differentially activated by upstream guanine nucleotide exchange factors (Jones, M. K., and Jackson, J. H. (1998) J. Biol. Chem. 273, 1782-1787), indicate that each of the four Ras proteins may qualitatively or quantitatively participate in distinct signaling cascades and have significantly different biological roles in vivo. Importantly, these studies also suggest for the first time that the distinct and likely cooperative biological functions of the Ki-ras-encoded Ki-Ras 4A and Ki-Ras 4B proteins may help explain why constitutively activating mutations of Ki-ras, but not N-ras or Ha-ras, are frequently detected in human carcinomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358073     DOI: 10.1074/jbc.274.24.17164

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

Review 1.  A Ras by any other name.

Authors:  D Bar-Sagi
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

2.  cPLA2 regulates the expression of type I interferons and intracellular immunity to Chlamydia trachomatis.

Authors:  Mark J Vignola; David F Kashatus; Gregory A Taylor; Christopher M Counter; Raphael H Valdivia
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

3.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

4.  H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis.

Authors:  Sandrine Roy; Bruce Wyse; John F Hancock
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

5.  Elevated phospholipase D activity in H-Ras- but not K-Ras-transformed cells by the synergistic action of RalA and ARF6.

Authors:  Lizhong Xu; Paul Frankel; Desmond Jackson; Thuy Rotunda; Rita L Boshans; Crislyn D'Souza-Schorey; David A Foster
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

6.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

7.  Mammalian mRNA splice-isoform selection is tightly controlled.

Authors:  Jennifer L Chisa; David T Burke
Journal:  Genetics       Date:  2006-12-18       Impact factor: 4.562

Review 8.  Defining the cancer master switch.

Authors:  Courtney J Balentine; David H Berger; Shi-He Liu; Changyi Chen; John Nemunaitis; F Charles Brunicardi
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

9.  Proteomic and phosphoproteomic alterations in benign, premalignant and tumor human breast epithelial cells and xenograft lesions: biomarkers of progression.

Authors:  So Hee Kim; Fred R Miller; Larry Tait; Jie Zheng; Raymond F Novak
Journal:  Int J Cancer       Date:  2009-06-15       Impact factor: 7.396

10.  Ras membrane orientation and nanodomain localization generate isoform diversity.

Authors:  Daniel Abankwa; Alemayehu A Gorfe; Kerry Inder; John F Hancock
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.